Clinical

Theranos, the embattled blood testing startup, is now under investigation by the U.S. Securities and Exchange Commission, as well as the U.S. Attorney's Office for the Northern District of California, according to Bloomberg. The investigation is the latest in a series of hardships for the once-vaunted company, coming on the heels of a recommendation by the Centers for Medicare and Medicaid Services that founder Elizabeth Holmes be banned from the blood testing business for a two-year period. In March, a study in the Journal of Clinical Investigation found that cholesterol test results obtained through Theranos – which are drawn from small finger pricks – were much different than those from large laboratory companies, implying that doctors' medical decisions could be thrown off by results acquired through Theranos technology. [Also: Theranos results differed from Quest, LabCorp enough to impact care decisions, study finds] In all, Theranos' results for total cholesterol were found to be an average 9.3 percent lower than those obtained through clinical laboratories Quest and LabCorp, according to the March study. This has lead researchers to surmise that in some instances, doctors may inappropriately begin, or fail to begin, statin therapy, a drug-based regimen that aims to prevent heart disease. The investigation by the SEC, which ensures companies give accurate information to investors, was one of several described in a memo from Theranos (once valued at $9 billion) obtained by Bloomberg. The memo was originally furnished to Theranos' partners including Walgreen's, which has reportedly been looking to cut ties with the startup. "The company continues to work closely with regulators and is cooperating fully with all investigations," Theranos officials said. Before the federal investigations were announced Monday, Holmes appeared on NBC's Today show to say she was "devastated" that her lab did not discover its deficiencies. Holmes also said Theranos would rebuild its lab from scratch to avoid future problems. In addition to suggesting that Holmes be temporarily banned from the industry, CMS has proposed a number of other sanctions, including revocation of Theranos' Clinical Laboratory Improvement Amendments of 1988 certificate – or, alternatively, a civil monetary penalty of $10,000 per day for each day of non-compliance. Theranos could delay the effective date of the sanctions by filing an appeal. Twitter: @JELagasse Like Healthcare IT News on Facebook and LinkedIn

Healthcare analytics company Decision Resources Group is growing its healthcare data trove in a big way, adding claims and electronic health record data for its new Real World Evidence repository, or RWE. DRG touts the fact that RWE, meant to offering its clients better patient insights and help them do longitudinal analytics, covers 90 percent of the U.S. healthcare system The company did not release the cost of the data acquired. Brigham Hyde, senior vice president of analytics and chief data officer at DRG, said the amount of data it now has available for licensing to its clients – all of it de-identified – far surpasses that offered by Truven and other data companies. "We have four times as many patients as Truven has and six times as many claims, and we have EHR detail," Hyde said. IBM announced February 18 it would purchase analytics company Truven, adding a massive repository of data to its Watson Health Cloud. [Also: IBM Watson buying Truven Health Analytics for $2.6 billion] DRG is expanding its expertise to offer its clients more complete and dynamic analyses in the following areas: health economics and outcomes research, epidemiology validation, patient-level forecasting and market sizing, patient-level compliance and real-time network influence. The RWE data asset comes from multiple data providers in the U.S. and includes patient, healthcare professional and payer-level analysis. "As healthcare continues its shift from volume to value, DRG's RWE repository enables academic grade analysis of the cost centers of healthcare in the U.S., as well as the behaviors and outcomes of treatment and coverage decisions," Hyde said. The repository covers 240 million unique U.S. patients with more than five years of historical data, and has 3.2 billion medical and pharmacy claims, enabling closer analysis of cost and outcomes data, according to DRG. Hyde said DRG would leverage its nearly 400 analysts worldwide to provide customers with disease specific insights. For example, the repository has strong coverage of Type 2 diabetes, along with payment details, lab values and clinical progress of patients. DRG also is using the RWE repository to make available custom and interactive analytic dashboards and analytics to enable clients to answer important business questions quickly. In a separate announcement today, DRG said the board of directors appointed Jonathan Sandler CEO. Sandler also serves as DRG chairman of the board.

Big screens in every hospital unit show quality and safety indicators for doctors, nurses, patients and family members. Children’s has reduced urinary tract infections while improving medication safety and time to treatment.

Kaiser Permanente this week launched a new database that enables researchers to examine participants' DNA in conjunction with environmental and behavioral health.

The Centers for Medicare and Medicaid Services has warned Theranos founder Elizabeth Holmes that the company could face serious sanctions after the startup failed to address numerous problems with its technology and practices.

Rosemary Ventura, Director of Nursing Informatics at New York Presbyterian Hospital, discusses the organization's strategic emphasis on improving clinical workflows and mobility in nursing on HIMSS Radio, hosted by Justin Barnes.

Cleveland Clinic clinicians will be available for on-demand visits at CVS Health MinuteClinics in Ohio via technology from American Well.

In his first year at the helm of Geisinger Health System, David Feinberg, MD, has continued to hone the longtime population health leader's intense focus on evidence-based care and improved patient experience.

The industry veteran said he envisions a focus on ‘life experience’ in healthcare that delivers precise treatments that are better suited to patients’ specific needs.

Family Medical Specialists in Florida is using care management technology to get paid under CPT code 99490, and the practice has already gotten buy-in from almost every eligible patient.